Nilo Therapeutics Launches with $101M to Target Immune Disease
Nilo Therapeutics launched with a $101 million Series A led by The Column Group, DCVC Bio, and Lux Capital,...
Pioneering Orphan Drug Updates from Sharp Therapeutics in 2025
No human data were disclosed. Sharp Therapeutics plans to present a Phase 1–ready preclinical package for its small‑molecule candidate...
Nurexone Shows Vision Recovery in Preclinical Glaucoma Model
Preclinical data from an optic nerve crush model showed that ExoPTEN, an exosome-delivered PTEN siRNA, produced a reproducible, dose-dependent...
Aardvark Gets FDA Alignment for Prader-Willi Phase 3 Trial
Aardvark Therapeutics lowered the minimum age of eligibility in its Phase 3 HERO trial of ARD-101 for hyperphagia in...
FDA Clears Promising Schizophrenia Drug for Phase 3 Trial
In a 189‑patient Phase 2 study, Celon Pharma’s PDE10A inhibitor CPL’36 delivered statistically significant symptom reductions at four weeks...
New Parkinson’s Drug GT-02287 Shows Promising Phase 1b Data
Early interim data from Gain Therapeutics’ Phase 1b study of GT-02287 in Parkinson’s disease point to stability and improvements...
Theriva Presents Next-Gen Oncolytic Adenovirus VCN-12 at ESGCT
Preclinical biodistribution and toxicity results from intracranial dosing of VCN-01 in a Syrian hamster model support feasibility for brain...
Verrica Presents New VP-315 Data for Basal Cell Carcinoma
No efficacy or safety data accompanied the announcement. Verrica said the SITC presentation will report an exploratory analysis from...
Neurona Expands NRTX-1001 Cell Therapy Trial for Epilepsy
In updated Phase 1/2 data for unilateral mesial temporal lobe epilepsy (MTLE), a single low dose of NRTX-1001 produced...
Innovative Heartworm Breath Test Completes First Phase Study
Global Innovative Platforms completed a 12‑month, >100‑sample feasibility effort evaluating breath-based detection of canine heartworm infection, to enable point‑of‑care...